Introduction 1
Influenza is one of the primary infectious diseases affecting public health. H1N1 2 and H3N2 subtypes of human influenza A and type B viruses cause seasonal influenza 3 with high morbidity and mortality, especially in pediatric, geriatric, and 4 immunocompromised patients (25) . In addition to the clinical aspects of these infections, 5 influenza epidemics also have a significant impact on our social economy (14) . Further, 6 viruses possessing hemagglutinin (HA) and neuraminidase (NA) to which humans are 7 immunologically naïve have the potential to cause global outbreaks or "pandemics". 8
Rapid diagnosis of influenza during the early stage of infection allows physicians 9 the opportunity to limit the infection and its sequelae by administering the appropriate 10 antiviral drugs to the patient. NA inhibitors (i.e., oseltamivir and zanamivir), which are 11 widely used to treat influenza, must be administered 36-48 h after the onset of symptoms 12 for maximal therapeutic efficacy (18). It is, however, difficult to distinguish influenza 13 from other acute respiratory disorders based purely on clinical signs and symptoms. The 14 availability of a diagnostic test with high sensitivity that can accommodate the large 15 volume of clinical specimens generated during influenza epidemics and pandemics, and 16 that is simple and quick is the holy grail of influenza diagnostics. 17
IRDTs that are currently commercially available in Japan (Table 1 ). There were 3 variations among these IRDTs in shape, method of specimen collection, detection 4 mechanism, time required to obtain results, storage temperature, and shelf life. The 5 fundamental detection principle, however, was identical: viral protein contained in the 6 test specimen was detected based on an antigen-antibody reaction with monoclonal 7 antibody(s) specific for nucleoprotein (NP), which is one of the most abundant proteins in 8 influenza virions and shares relatively high homology in both type A and type B viruses 9 (20). Therefore, the sensitivity of the IRDTs was dependent on the level of cross-10 reactivity of the NP-specific antibody(s) used with the viruses. The dilution rates of the 11 collected specimen (see footnote to for quarantine procedures to avoid the possible spread of infection. We, therefore, 15 examined the detection sensitivity of these IRDTs to six human (Table 5 ) and ten avian 16 (Table 6) (19), H7N7 (9, 16), and H9N2 (21)] have been reported. It is important, therefore, that 10
IRDTs be able to detect human infection with viruses of such unusual subtypes. However, 11 when we examined the detection sensitivity of our IRDTs to four avian isolates of non-12 H5N1 subtypes, we found that, regardless of the IRDTs tested, all four avian viruses 13 required relatively higher virus titers (> 10 4 TCID 50 with one exception) for a positive 14 reaction (Table 7 ). This finding suggests that these IRDTs are not applicable for several 15 subtypes of avian viruses, displaying relatively low sensitivity. to pandemic (H1N1) 2009 viruses, we used three isolates. As shown in Table 8 , at least 22 (H1N1) and A/Wisconsin/WSLH049/09 (H1N1) viruses, whereas A/Osaka/164/09 1 (H1N1) was more readily detected by some IRDTs. The overall trend of detection was 2 consistent among the IRDTs. Since these three isolates were propagated in MDCK cells 3 under the same conditions and share 99.8%-100% amino acid sequence homology in NP, 4 it is not clear why there were differences in sensitivity among the virus strains. 5
Finally, we evaluated the detection sensitivity of the IRDTs to pandemic (H1N1) 6
2009 viruses in our clinical specimens. Specifically, we used nasal swabs collected from 7 three patients infected with pandemic (H1N1) 2009 influenza viruses (Table 3) . Of the 8 nine IRDTs tested, ESPLINE® Influenza A & B-N was the most sensitive for detecting 9 pandemic viruses in our clinical specimens, as was the case with most of the viruses in 10 cell culture fluids tested above (Table 9) . Importantly, some IRDTs failed to detect any 11 viral antigens even with clinical specimens containing more than 10 5 pfu/ml of virus. 12
These results suggest that the IRDTs tested in this study can be used to b For all IRDTs examined, the test specimen (A) was required to be suspended in a diluent (B). Subsequently, all or part of the diluent 4 (C) was subjected to the assay. Dilution rates were calculated using the following formula: volume C / (volume A + volume B) x 100. c Based on their format, all IRDTs examined were divided into one of two types: Well format; the diluted specimen is dropped onto the 1 wells and the reaction occurs inside a covered plastic body, and Test strip format; the test strip is dipped into the diluted specimens 2 and the reaction occurs on the strip. 3 
